Arvinas Operations, Inc.

Huyabio International, LLC

Inspirna, Inc.

Akamara Therapeutics, Inc.

Huya Bioscience International, LLC

Hayley Reece

Gary Elliott

Mireille Gillings

Robert Goodenow

Suzanne J Romano

Royal J Haskell, Iii

Chungpin Herman Chen

Curtis Tyree

Saurabh Chitre

Joseph Edward Gordon Benson

Sarah Collins

Hanqing Dong

Jonathan James Loughrey

Attilia Figini

Stephen Wald

John A Grosso

Rhys Lloyd

Katharine Victoria Boulton

Sarkar Arindam

Laura E N Allan

Gavin Pringle

Ivan Ruggiero

The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl)piperidin-4-yl)methyl)piperazin-1-yl)-1- oxoisoindolin-2-yl)piperidine-2,6-dione, methods of making these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer.

Crystalline and amorphous forms of a compound for the targeted degradation of estrogen receptor

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same

Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.

Sulcardine salts

The present invention relates to new polymorphs of LXR&#x3b2; agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXR&#x3b2; agonist, as well as methods of treating cancer including administration of a formulation including an LXR&#x3b2; agonist to a subject in need thereof.

Polymorphs and uses thereof

The present disclosure relates to pharmaceutical sciences and chemical sciences. In particular, the present disclosure provides crystalline platinum-based compound IO-125, compositions and formulations comprising the same, along with method of preparing said crystalline compound, and uses thereof. 

Crystalline platinum-based compounds

Growing community of inventors

Dalkeith, United Kingdom

Hayley Reece